Literature DB >> 1825038

HLA class II (DR and DQ) antigen associations in idiopathic dilated cardiomyopathy. Validation study and meta-analysis of published HLA association studies.

J F Carlquist1, R L Menlove, M B Murray, J B O'Connell, J L Anderson.   

Abstract

We previously reported antigen frequency differences for HLA-DR4 and HLA-DRw6 between idiopathic dilated cardiomyopathy (IDC) patients and healthy controls in a pilot study. To confirm these findings, we undertook an independent study with a prospective hypothesis regarding the frequencies of DR4 and DRw6; typing for a second family of class II antigens (HLA-DQ) was included because of the proximity of the DQ loci to the DR loci and the strong linkage disequilibrium between some of the DR and DQ alleles. Comparing a new consecutive series of IDC patients (n = 41) and healthy blood bank controls (n = 53), we confirmed an increase of DR4 antigen frequency in patients (49% versus 21%, p less than 0.005). A trend toward decreased expression of DRw6 among patients was also noted (10% of patients versus 23% of controls). HLA-DQw4 was significantly elevated in patients compared with controls (27% versus 6%, p less than 0.005; relative risk, 6.1; etiologic fraction, 0.22). We identified the combined DR4-DQw4 haplotype in five of 41 Caucasian IDC patients (12%) and none of 53 controls (p less than 0.007). A comparison of specific antigen frequencies between the preliminary and validation studies did not reveal significant differences; therefore, the data from the two studies were examined in combination. For the combined studies, DR4 was elevated (51% versus 27% in controls, p less than 0.001), and DRw6 was decreased (9% versus 24% in controls, p less than 0.01). The relative risk for DR4 was 2.8, and the etiologic fraction was 0.33.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1825038     DOI: 10.1161/01.cir.83.2.515

Source DB:  PubMed          Journal:  Circulation        ISSN: 0009-7322            Impact factor:   29.690


  33 in total

1.  Idiopathic dilated cardiomyopathy: familial prevalence and HLA distribution.

Authors:  C J McKenna; M B Codd; H A McCann; D D Sugrue
Journal:  Heart       Date:  1997-06       Impact factor: 5.994

2.  Toward the primary prevention of idiopathic dilated cardiomyopathy.

Authors:  S S Coughlin
Journal:  J Natl Med Assoc       Date:  1991-11       Impact factor: 1.798

Review 3.  Cardiac Autoimmunity: Myocarditis.

Authors:  William Bracamonte-Baran; Daniela Čiháková
Journal:  Adv Exp Med Biol       Date:  2017       Impact factor: 2.622

Review 4.  Role of impaired central tolerance to α-myosin in inflammatory heart disease.

Authors:  HuiJuan Lv; Myra A Lipes
Journal:  Trends Cardiovasc Med       Date:  2012-08-16       Impact factor: 6.677

5.  Do specific HLA antigens predispose to ischaemic heart disease or idiopathic dilated cardiomyopathy?

Authors:  S C Grant; S Sheldon; P A Dyer; R D Levy; N H Brooks
Journal:  Br Heart J       Date:  1994-01

6.  SLC6A3 is a risk factor for Parkinson's disease: a meta-analysis of sixteen years' studies.

Authors:  Desheng Zhai; Songji Li; Ying Zhao; Zhicheng Lin
Journal:  Neurosci Lett       Date:  2013-11-07       Impact factor: 3.046

7.  Increases in circulating T lymphocytes expressing HLA-DR and CD40 ligand in patients with dilated cardiomyopathy.

Authors:  Atsuko Ueno; Kagari Murasaki; Nobuhisa Hagiwara; Hiroshi Kasanuki
Journal:  Heart Vessels       Date:  2007-09-20       Impact factor: 2.037

Review 8.  Molecular basis of hypertrophic and dilated cardiomyopathy.

Authors:  A J Marian; R Roberts
Journal:  Tex Heart Inst J       Date:  1994

9.  HLA-DRB1 gene polymorphism in patients with dilated cardiomyopathy.

Authors:  Q Wang; Y Liao; F Gong; H Mao; J Zhang
Journal:  J Tongji Med Univ       Date:  2000

Review 10.  Recent insights into the role of autoimmunity in idiopathic dilated cardiomyopathy.

Authors:  Jason M Lappé; Clara M Pelfrey; W H Wilson Tang
Journal:  J Card Fail       Date:  2008-05-27       Impact factor: 5.712

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.